Boosting lysosomal function and targeting neuroinflammation using a small compound for the treatment of Sanfilippo syndrome
The Sanfilippo Children’s Foundation and Fondation Sanfilippo Suisse have awarded an Incubator Grant to Dr. Johannes Schlachetzki and his colleague Assistant Professor Dr. Philip Gordts at the University of California San Diego. The team will investigate whether a drug in development for other neurodegenerative diseases shows promise as a therapeutic candidate for Sanfilippo syndrome.
The childhood dementia Sanfilippo syndrome is a complex disease that leads to progressive neurodegeneration. There is mounting evidence that neuroinflammation contributes to the disease symptoms and progression in Sanfilippo syndrome and other neurodegenerative diseases. Anti-inflammatory therapies are thus a growing research area for the disease, with the hope of slowing down the disease or easing symptoms.
Recently, a molecule called C381 was shown to reduce brain inflammation and neurodegeneration in mouse models for Parkinson’s disease and Batten disease. The latter, like Sanfilippo syndrome, is a lysosomal storage disorder that causes childhood dementia. In the two models, C381 was also shown to improve the function of the lysosomes, the compartments inside cells that help to degrade harmful material and recycle waste products.
With the funds from this grant, the team hopes to increase lysosomal activity and reduce neuroinflammation using C381 in a mouse model of Sanfilippo syndrome type A. Although a type A mouse model will be used, the results from this study could likely be transferable to other subtypes of Sanfilippo syndrome.
The team will determine whether C381 can reduce neuroinflammation and neurodegeneration in mice with Sanfilippo. They will take an in-depth look at how C381 affects lysosomes and neuroinflammation by breaking down the key molecular steps involved in the process. In particular, they will investigate a family of gene modulators that are known to be involved in lysosome function and neuroinflammation.
“Anti-neuroinflammatory therapies represent one emerging therapeutic avenue for Sanfilippo and many other neurodegenerative diseases,” said Dr Lisa Melton, Head of Research at the Sanfilippo Children’s Foundation. “This project could open up a potential new therapy option for Sanfilippo that has already shown promise in other similar diseases.”
Dr Johannes Schlachetzki is a clinical neurologist and researcher whose work centres on the brain immune response and how it can be therapeutically targeted to treat neurological diseases like Alzheimer’s, Parkinson’s, and lysosomal storage disorders.
- Project title: Boosting lysosomal function and targeting neuroinflammation using a small compound for the treatment of Sanfilippo syndrome
- Chief investigator: Dr Johannes Schlachetzki
- Amount: $50,000 from Sanfilippo Children’s Foundation and $50,000 from Fondation Sanfilippo Suisse
- Duration: 1 year
- Location: University of California San Diego
- Status: Active
- Start date: January 2023
* Type A will be studied in this project, but findings may be applied to all types of Sanfilippo